

# Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

<https://marketpublishers.com/r/CB66E37C122EN.html>

Date: May 2017

Pages: 466

Price: US\$ 2,000.00 (Single User License)

ID: CB66E37C122EN

## Abstracts

Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 14, 38, 23, 85, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).

The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Chronic Obstructive Pulmonary Disease (COPD) - Overview

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics

Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion

Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alteogen Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings

PLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc, H1 2017



Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Insmed Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Intech Biopharm Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production SpA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MedImmune LLC, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orchid Pharma Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis

Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Qu Biologics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SATT North SAS, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals GmbH & Co KG, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synedgen Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma

Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Inc, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corp, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm Co Ltd, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..1), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..2), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..3), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..4), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..5), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..6), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..7), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..8), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..9), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..10), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..11), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017  
(Contd..12), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017

(Contd..13), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017

(Contd..1), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017

(Contd..2), H1 2017

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017

(Contd..3), H1 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

### COMPANIES MENTIONED

Abeona Therapeutics Inc

Achillion Pharmaceuticals Inc

Adamis Pharmaceuticals Corp

Advanced Inhalation Therapies (AIT) Ltd

Advinus Therapeutics Ltd

AlgiPharma AS

Allinky Biopharma

Alteogen Inc

Amakem NV

Angiocrine Bioscience Inc

Angion Biomedica Corp

apceth Biopharma GmbH

Apellis Pharmaceuticals Inc

Aridis Pharmaceuticals LLC

Astellas Pharma Inc

AstraZeneca Plc

Asubio Pharma Co Ltd

Axikin Pharmaceuticals Inc

Bayer AG

Beech Tree Labs Inc

Bioneer Corp  
Boehringer Ingelheim GmbH  
C4X Discovery Holdings PLC  
Carolus Therapeutics Inc  
Cellular Biomedicine Group Inc  
Celon Pharma SA  
Chiesi Farmaceutici SpA  
Circassia Pharmaceuticals Plc  
CSL Ltd  
Cytokinetics Inc  
Daiichi Sankyo Company Ltd  
Diffusion Pharmaceuticals Inc  
Domainex Ltd  
Enterprise Therapeutics Ltd  
Errant Gene Therapeutics LLC  
F. Hoffmann-La Roche Ltd  
Foresee Pharmaceuticals LLC  
Galapagos NV  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Glenmark Pharmaceuticals Ltd  
Grifols SA  
Hanmi Pharmaceuticals Co Ltd  
iCeutica Inc  
InMed Pharmaceuticals Inc  
Innate Pharma SA  
Insmed Inc  
Intech Biopharm Ltd  
Invion Ltd  
Jiangsu Hansoh Pharmaceutical Group Co Ltd  
Johnson & Johnson  
KaloBios Pharmaceuticals Inc  
Kissei Pharmaceutical Co Ltd  
Kyowa Hakko Kirin Co Ltd  
Medestea Research & Production SpA  
MedImmune LLC  
Mereo Biopharma Group Plc  
Meridigen Biotech Co Ltd  
Microbion Corp

Novartis AG  
Odan Laboratories Ltd  
OPKO Health Inc  
Orchid Pharma Ltd  
Orion Oyj  
Pfizer Inc  
Pharmaxis Ltd  
Promedior Inc  
ProMetic Life Sciences Inc  
Proteostasis Therapeutics Inc  
Pulmagen Therapeutics LLP  
Pulmatrix Inc  
Qu Biologics Inc  
Quark Pharmaceuticals Inc  
Re-Pharm Ltd  
Regeneron Pharmaceuticals Inc  
Respira Therapeutics Inc  
Respiratorius AB  
rEVO Biologics Inc  
Rhizen Pharmaceuticals SA  
SATT North SAS  
Seoul Pharma Co Ltd  
sterna biologicals Gmbh & Co KG  
Sun Pharma Advanced Research Company Ltd  
Sunovion Pharmaceuticals Inc  
Synedgen Inc  
Syntrix Biosystems Inc  
Takeda Pharmaceutical Company Ltd  
Teva Pharmaceutical Industries Ltd  
Therabron Therapeutics Inc  
Theravance Biopharma Inc  
Torrent Pharmaceuticals Ltd  
Unizyme Laboratories A/S  
Vectura Group Plc  
Verona Pharma Plc  
Vertex Pharmaceuticals Inc  
Yuhan Corp  
Yungjin Pharm Co Ltd

## I would like to order

Product name: Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

Product link: <https://marketpublishers.com/r/CB66E37C122EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB66E37C122EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970